Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04127110
Title Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors European Organisation for Research and Treatment of Cancer - EORTC

lung non-small cell carcinoma



Age Groups: adult | senior
Covered Countries FRA | ESP | BEL

Additional content available in CKB BOOST